CA2890929A1 - Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses - Google Patents

Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses Download PDF

Info

Publication number
CA2890929A1
CA2890929A1 CA2890929A CA2890929A CA2890929A1 CA 2890929 A1 CA2890929 A1 CA 2890929A1 CA 2890929 A CA2890929 A CA 2890929A CA 2890929 A CA2890929 A CA 2890929A CA 2890929 A1 CA2890929 A1 CA 2890929A1
Authority
CA
Canada
Prior art keywords
substituted
heteroatoms selected
occurrence
nr11r11
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2890929A
Other languages
English (en)
French (fr)
Inventor
Ryan M. MOSLIN
Shuqun Lin
David S. Weinstein
Stephen T. Wrobleski
Yanlei Zhang
John S. Tokarski
Michael E. Mertzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2890929A1 publication Critical patent/CA2890929A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dermatology (AREA)
CA2890929A 2012-11-08 2013-11-07 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses Abandoned CA2890929A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723854P 2012-11-08 2012-11-08
US61/723,854 2012-11-08
PCT/US2013/068842 WO2014074660A1 (en) 2012-11-08 2013-11-07 ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES

Publications (1)

Publication Number Publication Date
CA2890929A1 true CA2890929A1 (en) 2014-05-15

Family

ID=49667568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2890929A Abandoned CA2890929A1 (en) 2012-11-08 2013-11-07 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses

Country Status (15)

Country Link
US (1) US9315494B2 (show.php)
EP (1) EP2922841B8 (show.php)
JP (1) JP6259463B2 (show.php)
KR (1) KR102233252B1 (show.php)
CN (1) CN104781252B (show.php)
AR (1) AR093403A1 (show.php)
AU (1) AU2013341185B2 (show.php)
BR (1) BR112015010244A8 (show.php)
CA (1) CA2890929A1 (show.php)
EA (1) EA028526B1 (show.php)
IL (1) IL238554A0 (show.php)
MX (1) MX2015005272A (show.php)
SG (1) SG11201503396UA (show.php)
TW (1) TWI620737B (show.php)
WO (1) WO2014074660A1 (show.php)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150953A1 (es) * 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
ES2648226T3 (es) 2012-11-08 2017-12-29 Bristol-Myers Squibb Company Compuestos de pirimidina sustituidos con alquilamida útiles en la modulación de IL-12, IL-23 y/o IFN
SG10201706897TA (en) 2012-11-08 2017-09-28 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alph responses
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
WO2016001341A1 (en) * 2014-07-03 2016-01-07 F. Hoffmann-La Roche Ag Sulfonylaminopyridine compounds, compositions and methods of use
WO2016022626A1 (en) * 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016210037A1 (en) 2015-06-24 2016-12-29 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
AR105112A1 (es) 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
AU2016359438B2 (en) * 2015-11-26 2019-05-02 Novartis Ag Diamino pyridine derivatives
CN109952303B (zh) 2016-10-14 2022-10-21 林伯士拉克许米公司 Tyk2抑制剂及其用途
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR102602558B1 (ko) * 2016-12-13 2023-11-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물
IL269036B2 (en) 2017-03-08 2023-03-01 Nimbus Lakshmi Inc tyk2 inhibitors, uses and methods for their production
JP7154229B2 (ja) 2017-05-11 2022-10-17 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ－４阻害剤として有用なチエノピリジンおよびベンゾチオフェン
TWI776810B (zh) * 2017-05-12 2022-09-11 瑞士商諾華公司 新穎二胺基吡啶衍生物
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
SG11202004592TA (en) * 2017-11-21 2020-06-29 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3752142A4 (en) 2018-02-13 2021-09-08 Rutgers, The State University of New Jersey ANTIBACTERIAL AGENTS: SOLUBLE SALTS AND AQUEOUS FORMULATIONS OF PYRONINS
WO2019160873A1 (en) 2018-02-13 2019-08-22 Rutgers, The State University Of New Jersey Antibacterial agents: o-alkyl-deuterated pyronins
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
JP7485609B2 (ja) * 2018-03-22 2024-05-16 ブリストル－マイヤーズ スクイブ カンパニー ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11414431B2 (en) 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
MX2021004562A (es) * 2018-10-30 2021-06-15 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos con amida para el tratamiento de condiciones relacionadas con la modulacion de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifn-alfa).
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
CN113271938A (zh) 2018-11-30 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
JP7570399B2 (ja) 2019-07-18 2024-10-21 ブリストル－マイヤーズ スクイブ カンパニー Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物
EP3999512B1 (en) 2019-07-18 2023-08-23 Bristol-Myers Squibb Company Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors
KR20220041124A (ko) 2019-07-23 2022-03-31 브리스톨-마이어스 스큅 컴퍼니 Irak4 억제제로서 유용한 티에노피리디닐 및 티아졸로피리디닐 화합물
ES2983263T3 (es) 2019-08-06 2024-10-22 Bristol Myers Squibb Co Compuestos heterocíclicos bicíclicos útiles como inhibidores de IRAK4
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
CN112203515B (zh) * 2020-03-11 2022-08-02 西北农林科技大学 N-苄基苯甲酰胺类化合物作为除草剂的用途
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
EP4143180A1 (en) * 2020-04-28 2023-03-08 Bristol-Myers Squibb Company Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators
US20230271942A1 (en) * 2020-08-07 2023-08-31 Pharmablock Sciences (Nanjing), Inc. Cdk9 inhibitor and use thereof
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
JP2023546996A (ja) 2020-10-23 2023-11-08 ニンバス クロソー， インコーポレイテッド Ｃｔｐｓ１阻害剤およびその使用
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
BR112023015590A2 (pt) 2021-02-02 2023-10-17 Liminal Biosciences Ltd Antagonistas de gpr84 e usos dos mesmos
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
WO2022175745A1 (en) * 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022175747A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2022175746A1 (en) * 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
MX2023009685A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
US20250051338A1 (en) 2021-10-25 2025-02-13 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
JP2025503448A (ja) * 2021-12-16 2025-02-04 リンク ファーマシューティカルズ シーオー．エルティーディー． Ｔｙｋ２阻害剤および組成物ならびにその方法
WO2023108536A1 (en) * 2021-12-16 2023-06-22 Lynk Pharmaceuticals Co. Ltd. Tyk2 inhibitors and compositions and methods thereof
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
JP2025513372A (ja) * 2022-04-19 2025-04-24 ブループリント メディシンズ コーポレイション Ｋｉｔ阻害剤
EP4532485A1 (en) * 2022-05-27 2025-04-09 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
WO2024249855A1 (en) * 2023-06-02 2024-12-05 Idrx, Inc. Combination therapy comprising kit inhibitors for use in the treatment of cancer
WO2025062372A1 (en) 2023-09-21 2025-03-27 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010058846A1 (ja) * 2008-11-21 2010-05-27 アステラス製薬株式会社 ４，６-ジアミノニコチンアミド化合物
CA2815330A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors

Also Published As

Publication number Publication date
AR093403A1 (es) 2015-06-03
EA028526B1 (ru) 2017-11-30
IL238554A0 (en) 2015-06-30
EP2922841A1 (en) 2015-09-30
BR112015010244A8 (pt) 2019-10-01
JP6259463B2 (ja) 2018-01-10
KR102233252B1 (ko) 2021-03-26
TW201422587A (zh) 2014-06-16
CN104781252A (zh) 2015-07-15
EA201590913A1 (ru) 2015-10-30
WO2014074660A1 (en) 2014-05-15
BR112015010244A2 (pt) 2017-07-11
SG11201503396UA (en) 2015-05-28
TWI620737B (zh) 2018-04-11
US20150307483A1 (en) 2015-10-29
CN104781252B (zh) 2017-11-17
EP2922841B8 (en) 2017-08-02
AU2013341185A1 (en) 2015-07-02
US9315494B2 (en) 2016-04-19
JP2016506368A (ja) 2016-03-03
AU2013341185B2 (en) 2017-07-13
MX2015005272A (es) 2015-07-14
KR20150081338A (ko) 2015-07-13
EP2922841B1 (en) 2017-06-07

Similar Documents

Publication Publication Date Title
AU2020203967B2 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP2922841B1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3066078B1 (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
HK40010074B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK40010074A (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses
HK1215255B (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn-alpha
BR112016010172B1 (pt) Compostos de piridila substituída por alquil- amida úteis no tratamento de uma doença inflamatória ou autoimune e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171107

FZDE Discontinued

Effective date: 20200831